In this podcast, we interviewed Jonathan Royce, Business Leader, Chromatography Resins, GE Healthcare Life Sciences, about the evolution of Protein A including the latest developments in Protein A chromatography resins. We also discussed what the future holds for this purification mainstay and how it can continue to address the changing needs of biopharma.
In this podcast, we interviewed Joakim Lundvist, Modality Manager, BioProcess™ Hardware, GE Healthcare about large-scale buffer management challenges. Buffer preparation is known to be one of the most resource-intensive activities in biomanufacturing as large volumes of buffers and process liquids are often required.
We examined the biggest challenges in buffer management and explored how technologies like inline conditioning can provide possible solutions.
In this podcast, we interviewed Alyssa Master, Ph.D., Senior Manager of Science and Applications, Nucleus Biologics about some of the challenges of working with FBS, why not all FBS is created equal and suggestions for FBS customers who are trying to navigate these issues.
We began the interview by discussing what FBS is and how it differs from other types of serum. Alyssa explained that FBS is a bi-product of the meat and dairy industry and it is great for in vitro cell growth because it contains a cocktail of growth factors. FBS is biochemically different from other sera like adult bovine serum or even newborn calf serum. Due to these biochemical differences, FBS has become the gold standard and as a result it is more expensive.
Alyssa continued that because of its ability to support cells in vitro it is widely used throughout academia, biotech, large pharma and bioproduction, particularly in cell therapy and vaccine biomanufacturing. I asked why so many use FBS and Alyssa said that it works well for most lines and is readily available. Because it is animal derived, it already contains cytokines and growth factors in the right combination to support cell growth.
View all show notes at:
011 - Do you have to sacrifice antibody titer for quality? Employing cell biology to get the best of both worlds
In this podcast, we interviewed Dr. Adam Elhofy, Ph.D., Chief Scientific Officer, Bio-Ess, about the relationship between antibody titer and product quality attributes such as glycosylation. Dr. Elhofy shares his thoughts on both challenges and opportunities for optimizing both high titer and glycosylation profiles.
In this podcast, we interviewed Ken Clapp, a senior member of GE Healhcare Life Sciences' upstream product management team. We discussed the use of single-use bioreactors for fermentation, how single-use technology has evolved to meet the more rigorous demands of fermentation, and the benefits of single-use for this application.
In this podcast, we interviewed Ken Clapp, a senior member of GE Healthcare Life Sciences' upstream product management team. We explored in more detail the implementation of single-use systems for microbial fermentation including which processes make good candidates for single-use and considerations for transitioning from stainless steel.
In this podcast, we interviewed Jim McGorry, CEO and Saverio LaFrancesca, President and Chief Medical Officer about how Biostage is using cell therapy to improve the standard of care in adult and pediatric esophageal disease.
We began the interview talking with Dr. LaFrancesca about how Biostage is using their Cellframe technology to improve on the current standard of care for esophageal diseases. Dr. LaFrancesca began by explaining that esophageal disease patients are divided into two patient populations - adults and pediatric. For adults affected by esophageal disease or cancer the standard of care is to pull up their stomach to meet the remaining portion of esophagus after resection or to remove a section of the intestine and use it to replace the removed portion. These surgical procedures are very complicated and involve surgeries into multiple body cavities. The mortality and morbidity rate for these treatments is very high and have serious associated complications. In most pediatric cases the babies are born without an esophagus and in this case there is no standard of care. The surgeon will utilize the same techniques used in adult cases, but there are serious consequences for the infants including failure to thrive and issues with growth.
007 - Improving lab productivity and reproducibility by taking a fresh look at existing workflows and protocols
In this podcast, we interviewed Sarah Simons, Automation Field Project Manager, Beckman Coulter Life Science, about how to improve lab productivity and reproducibility by "spring cleaning" your methods and taking a fresh look at existing workflows and protocols.
Sarah works on custom solutions for liquid handling systems. She joined Beckman in 2008, as an Automation Field Applications Specialist, focused on automated protocol development and customer training & support. Sarah enjoys taking a fresh look at existing workflows, and suggesting new solutions when transitioning a manual protocol to an automated process. Sarah studied Molecular Biology at University of New Hampshire, and worked in high throughput screening at Novartis prior to joining Beckman Coulter.
View Show Notes at http://cellculturedish.com/2017/04/improving-lab-pr…ws-and-protocols/
In this podcast, we interviewed Philip Mathuis, Co-founder and CEO, Ovizio, about cell culture monitoring, the latest technology for monitoring cells in culture without the need for sampling and where monitoring could move in the future.
Prior to co-founding Ovizio with Serge Jooris in 2010, Mr. Mathuis obtained an engineering degree in electronics and telecommunications. He started his career in the high-tech sector where he held management positions for large companies in several European countries. Here he developed strong business and commercial skills, completed by an MBA from ESCP, Paris. Leading and quickly positioning Ovizio as a key player in cell culture monitoring with a strong portfolio of innovative quantitative microscopy technologies is certainly one of his major career highlights.
Show Notes are available at: the Cell Culture Dish
In this podcast, we interviewed Hillary Kaplan, Director, Bioprocess CMC Development & Operations, Klein Hersh about the job outlook for the biomanufacturing industry from a recruiter's perspective.
Hillary partners with organizations ranging from VC backed start-ups and mid-size biotechs to large multinational biopharma companies in helping to identify individuals working exclusively in biologics/large molecule development. These scientific and operational leaders tend to be formally trained in Chemical/Biomolecular Engineering and are tasked with bridging the gap between R&D and development and readying products for manufacturing and launch.
To learn more and view show notes please visit: job-outlook-biomanufacturing-industry